Both CD123-CD28 and CD123-CD137 CAR+ T cell-treated groups showed similarly reduced tumor burdens compared with the untreated group, as measured by tumor BLI flux (Fig 5C). This evidence concerns the gene TNFRSF9 and neoplasm.